Clinical trials: Placebo Group
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S
Systemic Lupus Erythematosus
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
- Trial name
- BRAVE II (NCT03616964)
- Testing
- Baricitinib
- Where
- 159 sites in United States, Argentina and 13 more
- Volunteers
- 778 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
- Trial name
- NCT00077714
- Testing
- Paliperidone ER
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease
The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with…
- Trial name
- HESTIA 1 (NCT02214121)
- Testing
- Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Bronchial Asthma
Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma
The purpose of this study was evaluation the efficacy of antiepileptic drug phenytoin (diphenine) in the treatment of bronchial asthma.
- Trial name
- NCT00327028
- Testing
- Diphenine
- Volunteers
- 61 people
- Sponsor
- Centre of Chinese Medicine, Georgia
Overactive Bladder
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine.
- Trial name
- NCT01302067
- Testing
- Fesoterodine 8mg, Fesoterodine 4mg
- Where
- 293 sites in United States, Argentina and 25 more
- Volunteers
- 2,012 people
- Sponsor
- Pfizer
Mild Alzheimer Disease
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease
To evaluate the safety and efficacy of PM012 tablets for Alzheimer's disease, dose-finding study will be performed on phase 2b, and the established dose will be used for the non-inferiority phase 3 trial to evaluate the…
- Trial name
- PM012-2b (NCT05811000)
- Testing
- PM012, Donepezil
- Where
- South Korea
- Volunteers
- 312 people
- Sponsor
- Mediforum Ltd., Co.
Non Dystrophic Myotonia
Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)
The main objective of this study is to explore whether multiple trials with individual patients (N-of-1 trials) can produce a reliable evidence base for coverage decisions on clinical and cost-effectiveness of drug treatment for…
- Trial name
- NCT02045667
- Testing
- Mexiletine
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 872 sites in United States, Australia and 45 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Bronchogenic Carcinoma
Randomized Trial of Fluticasone in Bronchial Premalignancy
The purpose of this study is to assess the efficacy of fluticasone on the development of lung cancer in smokers
- Trial name
- NCT00407264
- Testing
- Fluticasone propionate
- Where
- 2 sites in Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Crohn Disease
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.
- Trial name
- TRIDENT (NCT02877134)
- Testing
- JNJ-64304500, Ustekinumab
- Where
- 147 sites in United States, Belgium and 12 more
- Volunteers
- 388 people
- Sponsor
- Janssen Research & Development, LLC
Renal Cell Carcinoma
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
- Trial name
- NCT00423332
- Testing
- Cediranib
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Diabetes Mellitus, Type 2
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
- Trial name
- NCT00716092
- Testing
- Sitagliptin, Linagliptin
- Where
- 3 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo.
- Trial name
- NCT00086671
- Testing
- ABT-874/Human monoclonal antibody against IL-12
- Where
- 44 sites in United States, Canada and 3 more
- Volunteers
- 215 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
IgA Nephropathy
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d.
- Trial name
- APPLAUSE-IgAN (NCT04578834)
- Testing
- LNP023
- Where
- 177 sites in United States, Argentina and 33 more
- Volunteers
- 518 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
- Trial name
- NCT00921804
- Testing
- AZD 8529, Risperidone
- Where
- 3 sites in United States
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Cancer, Neoplasms
A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
This study is an ascending dose first-time-in-human study to determine the safety, tolerability, pharmacodynamic (PD), and pharmacokinetics (PK) profile of GSK1795091 in healthy subjects.
- Trial name
- NCT02798978
- Testing
- GSK1795091
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
- Trial name
- NCT00679263
- Testing
- MN-221
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- MediciNova
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.